Why the study?
The high incidence of ACS warrants searching for new cardiac biomarkers, prompting the evaluation of serum MG-53 levels for ACS diagnosis and prognosis.
Does serum Mitsugumin-53 (MG-53) level serve as a diagnostic marker for acute coronary syndrome?
Does serum Mitsugumin-53 (MG-53) level serve as a diagnostic marker for acute coronary syndrome?
Serum MG-53 levels are significantly elevated in ACS patients and correlate with established myocardial injury markers, suggesting potential utility as a novel diagnostic biomarker.
Answers are grounded in this paper and cite their sources.
Serum MG-53 elevation was associated with ACS; leaves open diagnostic utility pending prospective validation.
BACKGROUND: The high incidence of acute coronary syndrome (ACS) warrants the search for new cardiac biomarkers. Mitsugumin-53 (MG-53) is a myokine involved in cell membrane repair and essential for the function and survival of cardiomyocytes. Therefore, the study assessed the utility of serum MG-53 levels in ACS diagnosis and prognosis. METHOD: We enrolled 120 ACS patients as cases and 40 healthy controls as per the inclusion and exclusion criteria in this case-control study. The demographics, present and past history, and physical characteristics were recorded. The chemistry analyzer analyzed routine blood investigations. Serum MG-53 and heart-type fatty acid binding protein (H-FABP as a myocardial injury marker) levels were measured using enzyme-linked immunosorbent assay (ELISA) kits. The Statistical Package for the Social Sciences (SPSS) program (version 26.0, IBM Corp., Armonk, NY) was used for statistical analysis, such as independent t-test, chi-squared test, Pearson's and Spearman's correlation, receiver operating characteristic (ROC) curve, and univariate and multivariate logistic regression. A p-value <0.05 was considered statistically significant. RESULTS: Patients with ACS as cases had higher serum MG-53 and H-FABP levels than controls (p < 0.001). Serum MG-53 level was significantly positively correlated with serum troponin-I (correlation coefficient (r) = 0.520, p < 0.001), creatine kinase-MB (r = 0.298, p = 0.001), and H-FABP (r = 0.792, p < 0.001). The ROC curve showed that the serum MG-53 level had an area under the curve of 0.846 (95% CI: 0.781-0.911, p < 0.001) and sensitivity and specificity of 70%. Multivariate logistic regression depicted that the serum MG-53 level (OR = 1.113, 95% CI: 1.028-1.297, p < 0.001) was significantly associated with ACS risk after adjusting for age, weight, systolic blood pressure, random blood glucose, and serum total cholesterol levels. Multivariate linear regression showed a significant positive association between serum MG-53 and H-FABP levels in patients with different ACS severity and vessel diseases (p < 0.001). Conclusion: The serum MG-53 level may be considered one of the diagnostic markers in ACS patients. However, further studies need to confirm our findings.
No takes yet. Share an insight, caveat, or question.
Pattabi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: